Nurix Therapeutics (NRIX) Other Accumulated Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Other Accumulated Expenses for 8 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Other Accumulated Expenses rose 25.14% year-over-year to $1.3 million; the TTM figure through May 2026 stood at $1.3 million (up 25.14% YoY), while the FY2025 annual figure was $2.1 million, down 7.87% from the prior year.
• Other Accumulated Expenses retreated to $1.3 million in Q2 2026 per NRIX's latest filing, from $1.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.7 million in Q1 2025 and bottomed at $551000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.4 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 272.71% — and 2023, when it slumped 50.03%.
• Nurix Therapeutics' Other Accumulated Expenses stood at $1.5 million in 2022, then plunged by 50.03% to $751000.0 in 2023, then jumped by 202.93% to $2.3 million in 2024, then decreased by 7.87% to $2.1 million in 2025, then slumped by 37.79% to $1.3 million in 2026.
• Business Quant data shows NRIX's Other Accumulated Expenses at $1.3 million in Q2 2026, $1.9 million in Q1 2026, and $2.1 million in Q4 2025.